Identification of miR-451 target genes as prognostic markers in diffuse large B-cell lymphoma
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.MicroRNA-451 (miR-451) suppresses B-cell lymphoma growth by inhibiting proliferation, arresting the cell cycle, and promoting apoptosis. Its target genes significantly impact Diffuse Large B-cell Lymphoma (DLBCL) patient prognosis.
Area Of Science
- Oncology
- Molecular Biology
- Genetics
Background
- B-cell lymphoma is a complex cancer with multiple regulatory factors.
- MicroRNAs (miRNAs) are key regulators in B-cell lymphoma initiation and progression.
- Further exploration of miRNA functions, including miR-451, is crucial for understanding B-cell lymphoma.
Purpose Of The Study
- To investigate the role of miR-451 in Diffuse Large B-cell Lymphoma (DLBCL).
- To identify miR-451 target genes and their association with DLBCL prognosis.
- To elucidate the mechanism by which miR-451 influences DLBCL development.
Main Methods
- Overexpression of miR-451 in human DLBCL cell lines (Romas, HBL-1).
- Cell proliferation, cell cycle, and apoptosis assays.
- Bioinformatics analysis of GEO datasets to identify differentially expressed genes (DEGs) and predict miR-451 targets.
- Development of a DLBCL prognostic risk model using Cox and LASSO regression.
- Validation of target gene expression using qRT-PCR.
Main Results
- miR-451 overexpression inhibited DLBCL cell proliferation.
- miR-451 induced cell cycle arrest and apoptosis in DLBCL cell lines.
- Bioinformatics analysis identified 9 significant target genes (MMP9, AQP9, RIN2, EOMES, LCP2, SELPLG, MAL, SOCS5, S1PR3) associated with DLBCL prognosis.
Conclusions
- miR-451 plays a suppressive role in DLBCL development.
- A specific set of miR-451 target genes significantly influences DLBCL patient outcomes.
- These findings suggest a potential therapeutic mechanism involving miR-451 in DLBCL treatment.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...